Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-26 @ 1:17 PM
Ignite Modification Date: 2025-12-26 @ 1:17 PM
NCT ID: NCT05161806
Description: Any signs or symptoms were collected throughout the study i.e. approximately 31 days
Frequency Threshold: 0
Time Frame: Adverse events were collected throughout the study i.e. approximately 31 days
Study: NCT05161806
Study Brief: Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
SOK583A1 (40 mg/mL) participants received a single dose of 2 mg SOK583 in 0.05 mL (40 mg/mL) and completed the study 0 None 0 30 3 30 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Intraocular pressure increased SYSTEMATIC_ASSESSMENT Investigations MedDRA version 24.1 View
Hypertension SYSTEMATIC_ASSESSMENT Vascular disorders MedDRA version 24.1 View
Foreign body sensation in eyes SYSTEMATIC_ASSESSMENT Eye disorders MedDRA version 24.1 View
Ocular discomfort SYSTEMATIC_ASSESSMENT Eye disorders MedDRA version 24.1 View